Skip to content

Mechanism Study on Cannabinoid Receptor CB1 Facilitating TGF-ß Receptor Endocytosis to Alleviate Idiopathic Pulmonary Fibrosis

Mechanism Study on Cannabinoid Receptor CB1 Facilitating TGF-ß Receptor Endocytosis to Alleviate Idiopathic Pulmonary Fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106379
Enrollment
Unknown
Registered
2025-07-23
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis

Interventions

Community-acquired pneumonia group:None
Control group:None

Sponsors

Shanghai Fifth Peoople's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. All patients with IPF met the diagnostic criteria for idiopathic pulmonary fibrosis established by the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society (ATS/ERS/JRS/ALAT) in 2018. 2. Patients with CAP met the diagnostic criteria of Chinese Guidelines for the Diagnosis and treatment of adult CAP (2016 edition); 3. The patient was not combined with tumors, such as lung cancer, lung malignant tumors, etc. 4. The patient had not used glucocorticoids in the month before enrollment.

Exclusion criteria

Exclusion criteria: 1. Combined with or having a history of radiation pneumonitis, sarcoidosis, or pneumoconiosis; 2. Lung lesions caused by occupational factors, medications, environmental factors, cardiac insufficiency, etc. 3. Presence of severe conditions such as hypertension, heart disease, abnormal liver function, or abnormal renal function; 4. Patients who are pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Pulmonary function;

Secondary

MeasureTime frame
Disease progression assessment;

Countries

China

Contacts

Public ContactQing Liang

Shanghai Fifth Peoople's Hospital

liangqing@5thhospital.com+86 21 24289465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026